An overview of the efficacy and safety of β ₂ -adrenoceptor antagonists for the treatment of chronic obstructive pulmonary disease

Introduction The safety of β2-AR antagonists in the treatment of patients with COPD continues to be a topic of research and discussion within the medical community. Emerging evidence suggests potentially benefits in the management of this complex respiratory condition. However, antagonists display a minimal preference for β2-AR over β1-AR present a complex therapeutic challenge in COPD management, necessitating an understanding of small differences in their pharmacological profiles and clinical implications.